Premium
A rare variant in EZH2 is associated with prostate cancer risk
Author(s) -
Raspin Kelsie,
FitzGerald Liesel M.,
Marthick James R.,
Field Matt A.,
Malley Roslyn C.,
Banks Annette,
Donovan Shaun,
Thomson Russell J.,
Foley Georgea R.,
Stanford Janet L.,
Dickinson Joanne L.
Publication year - 2021
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.33584
Subject(s) - prostate cancer , junb , biology , prostate , ezh2 , cancer research , allele , cancer , gene , genetics , medicine , oncology , gene expression
Prostate cancer (PrCa) is highly heritable, and although rare variants contribute significantly to PrCa risk, few have been identified to date. Herein, whole‐genome sequencing was performed in a large PrCa family featuring multiple affected relatives spanning several generations. A rare, predicted splice site EZH2 variant, rs78589034 (G > A), was identified as segregating with disease in all but two individuals in the family, one of whom was affected with lymphoma and bowel cancer and a female relative. This variant was significantly associated with disease risk in combined familial and sporadic PrCa datasets (n = 1551; odds ratio [OR] = 3.55, P = 1.20 × 10 −5 ). Transcriptome analysis was performed on prostate tumour needle biopsies available for two rare variant carriers and two wild‐type cases. Although no allele‐dependent differences were detected in EZH2 transcripts, a distinct differential gene expression signature was observed when comparing prostate tissue from the rare variant carriers with the wild‐type samples. The gene expression signature comprised known downstream targets of EZH2 and included the top‐ranked genes, DUSP1 , FOS , JUNB and EGR1 , which were subsequently validated by qPCR. These data provide evidence that rs78589034 is associated with increased PrCa risk in Tasmanian men and further, that this variant may be associated with perturbed EZH2 function in prostate tissue. Disrupted EZH2 function is a driver of tumourigenesis in several cancers, including prostate, and is of significant interest as a therapeutic target.